| Literature DB >> 32454512 |
Rui Shi1,2, Chao Shan3, Xiaomin Duan1,2, Zhihai Chen4, Peipei Liu5, Jinwen Song6, Tao Song1,7,8, Xiaoshan Bi1,9, Chao Han1,2, Lianao Wu9,10, Ge Gao3, Xue Hu3, Yanan Zhang3, Zhou Tong1,10, Weijin Huang11, William Jun Liu5, Guizhen Wu5, Bo Zhang3, Lan Wang11, Jianxun Qi10,12, Hui Feng13, Fu-Sheng Wang14, Qihui Wang15,16,17, George Fu Gao18, Zhiming Yuan19, Jinghua Yan20,21,22.
Abstract
An outbreak of coronavirus disease 2019 (COVID-19)1-3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus-receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32454512 DOI： 10.1038/s41586-020-2381-y
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962